Joincare Pharmaceutical Group Industry Co.,Ltd. (SHA:600380)
China · Delayed Price · Currency is CNY 11.27
+0.08 (0.71%)
Apr 8, 2026, 3:00 PM CST
SHA:600380 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 15,216 | 15,492 | 16,522 | 17,013 | 15,747 |
Other Revenue | - | 127.91 | 124.63 | 130.02 | 157.06 |
| 15,216 | 15,619 | 16,646 | 17,143 | 15,904 | |
Revenue Growth (YoY) | -2.58% | -6.17% | -2.90% | 7.79% | 17.62% |
Cost of Revenue | 5,714 | 6,099 | 6,608 | 6,380 | 5,778 |
Gross Profit | 9,501 | 9,521 | 10,039 | 10,763 | 10,126 |
Selling, General & Admin | 5,018 | 4,836 | 5,368 | 5,944 | 5,966 |
Research & Development | 1,273 | 1,435 | 1,662 | 1,742 | 1,397 |
Other Operating Expenses | 24.36 | 155.49 | 177.21 | 196.72 | 180.8 |
Operating Expenses | 6,315 | 6,431 | 7,224 | 7,885 | 7,553 |
Operating Income | 3,186 | 3,090 | 2,815 | 2,877 | 2,572 |
Interest Expense | - | -123.26 | -146.73 | -139.02 | -90.28 |
Interest & Investment Income | 71.49 | 481.67 | 611.73 | 451.45 | 263.85 |
Currency Exchange Gain (Loss) | - | 22.87 | 27.25 | 104.46 | -2.74 |
Other Non Operating Income (Expenses) | 207.12 | -17.81 | -7.69 | -9.62 | -4.89 |
EBT Excluding Unusual Items | 3,465 | 3,453 | 3,300 | 3,285 | 2,738 |
Gain (Loss) on Sale of Investments | 19.49 | -17.5 | -25.42 | -76.26 | -23.51 |
Gain (Loss) on Sale of Assets | 2.97 | 45.26 | -0.17 | -0.71 | 24.04 |
Asset Writedown | -120.79 | -30.09 | -3.27 | -31.51 | -8.25 |
Other Unusual Items | - | 123.81 | 194.75 | 280.06 | 221.66 |
Pretax Income | 3,366 | 3,575 | 3,466 | 3,456 | 2,952 |
Income Tax Expense | 501.28 | 592.14 | 614.54 | 561.8 | 339.48 |
Earnings From Continuing Operations | 2,865 | 2,983 | 2,851 | 2,894 | 2,613 |
Minority Interest in Earnings | -1,529 | -1,596 | -1,408 | -1,392 | -1,284 |
Net Income | 1,336 | 1,387 | 1,443 | 1,503 | 1,328 |
Net Income to Common | 1,336 | 1,387 | 1,443 | 1,503 | 1,328 |
Net Income Growth | -3.68% | -3.90% | -3.99% | 13.12% | 18.57% |
Shares Outstanding (Basic) | 1,830 | 1,874 | 1,898 | 1,894 | 1,935 |
Shares Outstanding (Diluted) | 1,830 | 1,874 | 1,898 | 1,897 | 1,937 |
Shares Change (YoY) | -2.36% | -1.30% | 0.07% | -2.07% | -0.97% |
EPS (Basic) | 0.73 | 0.74 | 0.76 | 0.79 | 0.69 |
EPS (Diluted) | 0.73 | 0.74 | 0.76 | 0.79 | 0.69 |
EPS Growth | -1.35% | -2.63% | -4.06% | 15.52% | 19.73% |
Free Cash Flow | 3,125 | 2,657 | 2,799 | 2,830 | 1,042 |
Free Cash Flow Per Share | 1.71 | 1.42 | 1.47 | 1.49 | 0.54 |
Dividend Per Share | - | 0.200 | 0.180 | 0.180 | 0.150 |
Dividend Growth | - | 11.11% | - | 20.00% | - |
Gross Margin | 62.44% | 60.96% | 60.31% | 62.78% | 63.67% |
Operating Margin | 20.94% | 19.78% | 16.91% | 16.78% | 16.18% |
Profit Margin | 8.78% | 8.88% | 8.67% | 8.77% | 8.35% |
Free Cash Flow Margin | 20.54% | 17.01% | 16.81% | 16.51% | 6.55% |
EBITDA | 3,972 | 3,866 | 3,837 | 3,683 | 3,167 |
EBITDA Margin | 26.11% | 24.75% | 23.05% | 21.48% | 19.91% |
D&A For EBITDA | 786.29 | 775.67 | 1,022 | 805.34 | 594.45 |
EBIT | 3,186 | 3,090 | 2,815 | 2,877 | 2,572 |
EBIT Margin | 20.94% | 19.78% | 16.91% | 16.78% | 16.18% |
Effective Tax Rate | 14.89% | 16.56% | 17.73% | 16.25% | 11.50% |
Revenue as Reported | - | 15,619 | 16,646 | 17,143 | 15,904 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.